Justin Walsh from JonesTrading maintains a Buy rating for BioLineRx, setting a $12 target, due to strategic advancements, including a new study for GLIX1 in glioblastoma and accelerated enrollment for motixafortide in pancreatic cancer. New U.S. intellectual property and a favorable ruling enhance the company's position.

NodeGuardian

2026-04-16 19:39:22

Abstract generation in progress

JonesTrading analyst Justin Walsh reiterated a Buy rating for BioLineRx with a $12 price target, citing strategic advancements in its pipeline. The company has initiated a Phase I/IIa study for GLIX1 in glioblastoma, with initial data expected in H1 2027, and is accelerating enrollment for a Phase IIb trial of motixafortide for metastatic pancreatic cancer. Additionally, new U.S. intellectual property protection for GLIX1 and a favorable arbitration ruling against Biokine Therapeutics further strengthen BioLineRx’s competitive and legal standing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes

Reward
2
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
178.62K Popularity
#
Gate13thAnniversaryLive
712.2K Popularity
#
AltcoinsRallyStrong
7.3M Popularity
#
AnthropicvsOpenAIHeatsUp
1.06M Popularity
#
KalshiFacesNevadaRegulatoryClash
454.36K Popularity

Sitemap

BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target

Trending Topics

GatePreIPOsLaunchesWithSpaceX

Gate13thAnniversaryLive

AltcoinsRallyStrong

AnthropicvsOpenAIHeatsUp

KalshiFacesNevadaRegulatoryClash

Pin